Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2

5(55.6%)

Phase 1

2(22.2%)

Phase 3

2(22.2%)

9Total

Phase 2(5)

Phase 1(2)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06264141Phase 2Completed

Evaluation of Nitric Oxide Nasal Spray (NONS) for Treatment of Recurrent Acute Rhinosinusitis

Role: lead

NCT05109611Phase 3Terminated

Nitric Oxide Nasal Spray (NONS) as Prevention for Treatment of Individuals at Risk of Exposure to COVID-19 Infection

Role: lead

NCT06120816Phase 1Completed

Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis

Role: lead

NCT05877313Phase 2Completed

Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts)

Role: lead

NCT04755647Phase 1Completed

Nitric Oxide Footbath for Treatment of Diabetic Foot Ulcers

Role: lead

NCT05599919Phase 3Completed

Nitric Oxide Nasal Spray (NONS) To Treat and Prevent the Exacerbation of Infection in Individuals With Mild COVID-19

Role: lead

NCT04163978Phase 2Completed

Nitric Oxide Releasing Sinus Irrigation (NOSi) to Treat Recalcitrant Chronic Rhinosinusitis (RCRS)

Role: lead

NCT04443868Phase 2Withdrawn

Nitric Oxide Releasing Solution to Treat and Prevent Exacerbation of Mild COVID-19 Infection

Role: lead

NCT04337918Phase 2Completed

Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection

Role: lead

All 9 trials loaded